Vyvgart Disease Interactions
There are 2 disease interactions with Vyvgart (efgartigimod alfa).
Efgartigimod alfa (applies to Vyvgart) infection
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Efgartigimod alfa may increase the risk of infection. Clinical studies have shown patients receiving efgartigimod alfa had below normal levels of white blood cell counts, lymphocytes, and neutrophils compared to placebo. Treatment with efgartigimod alfa should be delayed in patients with an active infection until the infection is resolved. During treatment, monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding efgartigimod alfa until the infection has resolved.
Efgartigimod alfa (applies to Vyvgart) vaccinations
Moderate Potential Hazard, Moderate plausibility.
Vaccination with live-attenuated or live vaccines is not recommended during treatment with efgartigimod alfa because efgartigimod alfa causes a reduction in IgG levels. It is recommended to be up-to-date with all required immunizations, as recommended by current immunization guidelines, before initiating a new treatment cycle.
Vyvgart drug interactions
There are 281 drug interactions with Vyvgart (efgartigimod alfa).
More about Vyvgart (efgartigimod alfa)
- Vyvgart consumer information
- Check interactions
- Compare alternatives
- Reviews (13)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: immune globulins
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.